TY - JOUR
TI - Human Papillomavirus Infections and Upper Aero-Digestive Tract Cancers:
The ARCAGE Study
AU - Anantharaman, Devasena
AU - Gheit, Tarik
AU - Waterboer, Tim and
AU - Abedi-Ardekani, Behnoush
AU - Carreira, Christine
AU - McKay-Chopin,
AU - Sandrine
AU - Gaborieau, Valerie
AU - Marron, Manuela
AU - Lagiou, Pagona
AU - and Ahrens, Wolfgang
AU - Holcatova, Ivana
AU - Merletti, Franco and
AU - Kjaerheim, Kristina
AU - Talamini, Renato
AU - Simonato, Lorenzo and
AU - Castellsague, Xavier
AU - Macfarlane, Tatiana V.
AU - Biggs, Anne-Marie
AU - and Thakker, Nalin
AU - Znaor, Ariana
AU - Thomson, Peter
AU - Canova,
AU - Cristina
AU - Conway, David I.
AU - Healy, Claire M.
AU - Tommasino,
AU - Massimo
AU - Pawlita, Michael
AU - Brennan, Paul
JO - JNCI Journal of the National Cancer Institute
PY - 2013
VL - 105
TODO - 8
SP - 536-545
PB - OXFORD UNIV PRESS INC
SN - 0027-8874, 1460-2105
TODO - 10.1093/jnci/djt053
TODO - null
TODO - Human papillomavirus (HPV) is causally implicated in a subset of cancers
of the upper aero-digestive tract (UADT).
Associations between type-specific HPV antibodies were examined among
1496 UADT cancer case subjects and 1425 control subjects by estimating
odds ratios (ORs) in logistic regression analyses adjusted for potential
confounders. The agreement between serology and tumor markers of HPV
infection, including presence of HPV DNA and p16 expression, were
examined in a subset of tumors.
HPV16 L1 seropositivity was associated with increased risk of oral
cavity and oropharyngeal cancer (OR 1.94, 95% confidence interval
[CI] 1.03 to 3.65; OR 8.60, 95% CI 5.21 to 14.20, respectively).
HPV16 E6 antibodies were present in 30.2% of oropharyngeal case
subjects and only 0.8% of control subjects (OR 132.0, 95% CI 65.29 to
266.86). Combined seropositivity to HPV16 E6 and E7 was rare (n 1 of
1425 control subjects). An agreement of 67% was observed between HPV16
E6 serology and the corresponding presence of an HPV-related cancer:
four of six HPV DNA-positive/p16-overexpressing tumors were HPV16 E6
antibody positive. An HPV16 independent association was observed for
HPV18 and oropharyngeal cancer (OR 8.14, 95% CI 2.21 to 29.99 for HPV18
E6 seropositivity) and HPV6 and laryngeal cancer (OR 3.25, 95% CI 1.46
to 7.24 for HPV6 E7 seropositivity).
These results confirm an important role for HPV16 infection in
oropharyngeal cancer. HPV16 E6 antibodies are strongly associated with
HPV16-related oropharyngeal cancers. Continuing efforts are needed to
consider both HPV serology and p16 staining as biomarkers relevant to
the etiology and natural history of HPV16-related oropharyngeal tumors.
These results also support a marginal role for HPV18 in oropharyngeal
cancer and HPV6 in laryngeal cancer.
ER -